Association of hepatic necrosis with trimethoprim sulfonamide administration in 4 dogs.
Hepatic necrosis in association with trimethoprim-sulfonamide (TMS) combination therapy was diagnosed in 4 dogs based on history, clinical presentation, and examination of histopathologic specimens collected postmortem. Duration of TMS therapy prior to onset of clinical signs ranged from 4 to 30 days. The dose of TMS ranged from 18 mg/kg to 53 mg/kg bid. Despite supportive medical therapy, all dogs died or were euthanized due to hepatic failure. This report highlights the potential for hepatotoxicity during TMS therapy. Duration of therapy, type of TMS combination, and dose did not appear related to the development of toxicity. The low number of dogs affected suggests an idiosyncratic drug reaction.
Twedt
D C
DC
Department of Clinical Sciences, College of Veterinary Medicine and Biomedical Sciences, Colorado State University, Fort Collins, USA.
Diehl
K J
KJ
Lappin
M R
MR
Getzy
D M
DM
D000818:Animals; D000890:Anti-Infective Agents / Q000009:adverse effects* / Q000627:therapeutic use; D001991:Bronchitis / Q000188:drug therapy / Q000662:veterinary; D056486:Chemical and Drug Induced Liver Injury; D004283:Dog Diseases / Q000139:chemically induced* / Q000188:drug therapy / Q000473:pathology; D004285:Dogs; D004305:Dose-Response Relationship, Drug; D005260:Female; D008099:Liver / Q000187:drug effects / Q000473:pathology; D008107:Liver Diseases / Q000473:pathology / Q000662:veterinary*; D008297:Male; D009336:Necrosis; D011711:Pyoderma / Q000188:drug therapy / Q000662:veterinary; D013997:Time Factors; D014295:Trimethoprim / Q000009:adverse effects* / Q000627:therapeutic use; D014552:Urinary Tract Infections / Q000188:drug therapy / Q000662:veterinary
D000890:Anti-Infective Agents; D014295:Trimethoprim